ACR Abstract #
Atacicept: 889, 2585, 2586, 2610; Sprifermin: 1207, 2183, 1L; Abituzumab: 774; Evobrutinib: 2565; Discovery Products: 25, 1060
Darmstadt, Germany, October 20, 2017 – Merck KGaA, Darmstadt, Germany, a leading science and technology company which operates its healthcare business in the U.S. and Canada as EMD Serono, today announced 11 abstracts are scheduled for presentation in oral and poster sessions, including one late-breaker, at the 2017 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting to be held November 3-8, 2017 in San Diego, CA, U.S. This data reflects the company’s resolute drive to pursue novel pathways and address areas of high unmet medical need for patients with chronic progressive diseases, particularly those of the immune system.
Noteworthy data includes a late-breaking abstract on FORWARD, a five-year Phase II study of sprifermin in OA of the knee, providing insights into its potential disease-modifying properties.
Additional data includes an oral presentation on the investigational agent atacicept in a subset of patients with high disease activity based on a post-hoc analysis of ADDRESS II, a 24-week, randomized, placebo-controlled Phase IIb study.
“We are committed to discovering and delivering transformative treatments to significantly improve the lives of people living with chronic progressive diseases,” said Luciano Rossetti, Executive Vice President, Global Head of Research & Development at the biopharma business of Merck KGaA, Darmstadt, Germany. “Our approach has led to the discovery of novel pathways that modulate the immune system in more targeted ways, based on preclinical models. We’re proud to showcase the progress we’ve made as we continue to explore the potential of these compounds that may eventually alter treatment paradigms.”
Other data of note include an updated safety analysis of ADDRESS II and its long-term extension study; an exposure-response and exposure-safety modelling analysis of ADDRESS II and the Phase II APRIL-SLE study; an in-vitro study of abituzumab for potential use in fibrotic diseases (or fibrosis); and a pharmacodynamics (PD) modelling study of evobrutinib, one of the first Bruton’s Tyrosine Kinase Inhibitors to be studied as a potential treatment in autoimmune diseases, with potential for eventual use in RA and SLE. All agents are investigational and have not been proven safe or effective, and are not registered in any market.
Accepted key abstracts at the 2017 ACR/ARHP Annual Meeting include:
|Title||Presenting Author||Abstract Number||Presentation Date/Time||Session Type/Title|
|Efficacy and Safety of Intra-Articular Sprifermin in Symptomatic Radiographic Knee Osteoarthritis: Results of the 2-Year Primary Analysis from a 5-Year Randomised, Placebo-Controlled, Phase II Study||M Hochberg||1L ||Tuesday, November 7, 4:30 PM - 6:00 PM PT||ACR Late-Breaking Abstract Session|
|Clinical Relevance of Structural Measures in Knee Osteoarthritis:|
Baseline Values and Change from Baseline Discriminate Patients
Subsequently Receiving Knee Replacement
|C Kwoh||1207||Monday, November 6, 9:00 AM – 11:00 AM PT||ACR Poster Session B: Osteoarthritis – Clinical Aspects Poster I: Clinical Trials and Interventions|
|Two-Year Changes in Knee Osteoarthritis Symptoms: Comparing|
Clinical Relevance of Patient-Reported Outcomes By Anchoring to Knee Replacement
|C Kwoh||2183||Tuesday, November 7, 9:00 AM – 11:00 AM PT||ACR Poster Session C: Osteoarthritis – Clinical Aspects Poster II: Observational and Epidemiological Studies|
|Attainment of Low Disease Activity By Patients with Systemic Lupus Erythematosus (SLE) Starting with High Disease Activity in a 24-Week, Randomized, Placebo-Controlled, Phase IIb Study of Atacicept (ADDRESS II)||J Merrill||889||Sunday, November 5, 2:30 PM – 4:00 PM PT||ACR Concurrent Abstract Session – Oral Presentation: Systemic Lupus Erythematosus – Clinical Aspects and Treatment I: Novel and Current Therapies|
|Safety Profile in SLE Patients Treated with Atacicept in a Phase IIb Study (ADDRESS II) and Its Extension Study ||J Merrill ||2585||Tuesday, November 7, 9:00 AM – 11:00 AM PT||ACR Poster Session C: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design|
|Exposure-Response Modelling and Exposure-Safety Modelling|
Analyses in Two Phase II Studies of Atacicept in SLE
|O Papasouliotis||2586||Tuesday, November 7, 9:00 AM – 11:00 AM PT||ACR Poster Session C: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design|
|QuantiFERON Testing in a Clinical Trial of Systemic Lupus Erythematosus: TB or Not TB ||N Goel||2610||Tuesday, November 7, 9:00 AM – 11:00 AM PT||ACR Poster Session C: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design|
|The ŠV Integrin Inhibitor Abituzumab Inhibits Myofibroblast Differentiation||E Samy||774||Sunday, November 5, 9:00 AM – 11:00 AM PT||ACR Poster Session A: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster I|
|Pharmacodynamic Modeling of BTK Occupancy Versus Efficacy in RA and SLE Models Using the Novel Specific BTK Inhibitor Evobrutinib||P Haselmayer||2565||Tuesday, November 7, 9:00 AM – 11:00 AM PT||ACR Poster Session C: Systemic Lupus Erythematosus – Animal Models Poster|
|A novel role for galectin-3 binding protein in B cell biology and antibody secretion||S Okitsu||25||Sunday, November 5, 9:00 AM – 11:00 AM PT||ACR Poster Session A: B Cell Biology and Targets in Autoimmune Disease Poster|
|Assessing interferon regulatory factor 5 (IRF5) function in human primary immune cells with cell-penetrating peptides ||G Chen||1060||Monday, November 6, 9:00 AM – 11:00 AM PT||ACR Poster Session B: Innate Immunity and Rheumatic Disease Poster II|
For more information about the data to be presented, please visit the ACR/ARHP website. Also, visit the EMD Serono booth at this year's Annual Meeting to learn more about the company's commitment to advancing innovation in immunological diseases.
Atacicept is in clinical development to investigate its potential as a treatment for systemic lupus erythematosus (SLE). It is a recombinant fusion protein which targets the cytokines APRIL and BlyS, two members of the tumor necrosis factor family that regulates B-cell maturation, function and survival and autoantibody production associated with certain autoimmune diseases such as SLE. Atacicept has been shown in animal models to affect several stages of B-cell development and may inhibit the survival of cells responsible for making antibodies. It is currently in Phase II studies.
Sprifermin is in clinical development to investigate its potential as a treatment for osteoarthritis (OA) in the knee. It is a truncated recombinant human FGF-18 protein thought to induce chondrocyte proliferation and increased extra-cellular matrix (ECM) production, with the potential of promoting cartilage growth and repair. Sprifermin is currently in Phase II studies.
Abituzumab is in clinical development to investigate its potential as a treatment for fibrotic diseases (or fibrosis). It is a recombinant de-immunized humanized IgG2 monoclonal antibody (mAb) that inhibits all subtypes of Šv integrins. Abituzumab is designed to block integrin-mediated activation of latent TGF-‚ and prevent fibroblast-to-myofibroblast transition, a key event in fibrosis. It is currently in Phase II studies.
Evobrutinib (M2951) is in clinical development to investigate its potential as a treatment for multiple sclerosis (MS), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). It is an oral, highly selective inhibitor of Bruton’s Tyrosine Kinase (BTK) which is important in the development and functioning of various immune cells including B lymphocytes and macrophages. Evobrutinib is designed to inhibit primary B cell responses such as proliferation and antibody and cytokine release, without directly affecting T cells. BTK inhibition is thought to suppress autoantibody-producing cells, which preclinical research suggests may be therapeutically useful in certain autoimmune diseases. Evobrutinib is currently in Phase II studies.
About EMD Serono, Inc.
EMD Serono is the biopharma business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada - a leading science and technology company - focused exclusively on specialty care. For more than 40 years, the business has integrated cutting-edge science, innovative products and industry-leading patient support and access programs. EMD Serono has deep expertise in neurology, fertility and endocrinology, as well as a robust pipeline of potential therapies in oncology, immuno-oncology and immunology as R&D focus areas. Today, the business has more than 1,100 employees around the country with commercial, clinical and research operations based in the company's home state of Massachusetts.